Related Experiment Video

Updated: Aug 18, 2026

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

Circulating cell-derived microparticles in Crohn's disease

Patrick Chamouard1, Dominique Desprez, Bénédicte Hugel

  • 1Service d'Hepato-Gastroentérologie, et d'Assistance Nutritive, Hôpital de Hautepierre, 67098 Strasbourg Cedex, France. Patrick.Chamouard@chru-strasbourg.fr

Digestive Diseases and Sciences
|April 7, 2005
PubMed

Insights

Circulating microparticles are elevated in Crohn's disease and infectious colitis. Infliximab therapy significantly reduces these microparticle levels in Crohn's disease patients, suggesting a link to inflammatory responses.

Area of Science:

  • Cell Biology
  • Immunology
  • Gastroenterology

Background:

  • Procoagulant membrane microparticles are released from activated or apoptotic cells.
  • These microparticles are implicated in various environmental stimuli and cellular processes.

Purpose of the Study:

  • To investigate the presence and levels of circulating microparticles in Crohn's disease (CD).
  • To assess the impact of infliximab therapy on microparticle levels in CD patients.

Main Methods:

  • Compared microparticle levels in CD patients, ulcerative colitis patients, infectious colitis patients, and healthy controls.
  • Assessed changes in microparticle levels after infliximab treatment in CD patients.

Main Results:

  • Elevated circulating microparticle levels were observed in CD and infectious colitis compared to ulcerative colitis and controls (P = 0.001).
  • Infliximab therapy significantly reduced microparticle levels in CD patients (from 10.33+/-1.20 to 6.45+/-0.90 nmol/L PS Eq; P = 0.002).

Conclusions:

  • Microparticle generation occurs in Crohn's disease.
  • Infliximab treatment leads to a significant decrease in circulating microparticles.
  • Microparticle release may be associated with the specific inflammatory response in Crohn's disease.

More Related Videos

Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies06:56

Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies

Published on: March 2, 2018

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...